Serum MicroRNA-122 Predicts Survival in Patients with Liver Cirrhosis

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Waidmann, Oliver ^a   Köberle, Verena ^a   Brunner, Friederike ^a   Zeuzem, Stefan ^a   Piiper, Albrecht ^a   Kronenberger, Bernd ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 122;

ADULT; ARTICLE; ASCITES; BACTERIAL PERITONITIS; BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HEPATORENAL SYNDROME; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PROGNOSIS; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME;

COHORT STUDIES; HUMANS; LIVER CIRRHOSIS; MICRORNAS; SURVIVAL ANALYSIS;

BACTERIA (MICROORGANISMS);

EID: 84866998947     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045652     Document Type: Article

References (29)

1. Cárdenas A, Ginès P, (2011) Management of patients with cirrhosis awaiting liver transplantation. Gut 60: 412-421.
2. European Association for the Study of the Liver, (2010) EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53: 397-417.
3. Garcia-Tsao G, Bosch J, (2010) Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 362: 823-832.
4. Wiesner RH, (2005) Patient selection in an era of donor liver shortage: Current US policy. Nat Clin Pract Gastroenterol Hepatol 2: 24-30.
5. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, et al. (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31: 864-871.
6. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, et al. (2001) A model to predict survival in patients with end stage liver disease. Hepatology 33: 464-470.
7. Kamath PS, Kim WR, (2007) The Model for End stage Liver Disease (MELD). Hepatology 45: 797-805.
8. Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jiménez W, et al. (2005) MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 41: 1282-1289.
9. Bambha K, Kim WR, Pedersen R, Bida JP, Kremers WK, et al. (2008) Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut 57: 814-820.
10. Ambros V, (2004) The functions of animal microRNAs. Nature 431: 350-355.
11. Kloosterman WP, Plasterk RH, (2006) The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450.
12. Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006.
13. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable bloodbased markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518.
14. Esquela-Kerscher A, Slack FJ, (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
15. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, et al. (2002) Identification of tissue-specific microRNAs from mouse. Curr Biol 12: 735-739.
16. Chang J, Nicolas E, Marks D, Sander C, Lerro A, et al. (2004) miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 1: 106-113.
17. Boutz DR, Collins PJ, Suresh U, Lu M, Ramírez CM, et al. (2011) Two-tiered approach identifies a network of cancer and liver disease-related genes regulated by miR-122. J Biol Chem. 286: 18066-18078.
18. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS, (2009) Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 28: 3526-3536.
19. Wang K, Zhang S, Weber J, Baxter D, Galas DJ, (2010) Export of microRNAs and microRNA-protective protein by mammalian cells. Nucl Acids Res 38: 7248-7259.
20. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, et al. (2009) Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 106: 4402-4407.
21. Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, et al. (2009) Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 55: 1977-1983.
22. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, et al. (2011) Circulating microRNAs as potential markers of human drug induced liver injury. Hepatology 5: 1767-1776.
23. Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, et al. (2010) Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 56: 1830-1838.
24. Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, et al. (2011) Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 106: 1663-1669.
25. Waidmann O, Bihrer V, Pleli T, Farnik H, Berger A, et al. (2012) Serum microRNA 122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat 19: e58-65.
26. Xu J, Wu C, Che X, Wang L, Yu D, et al. (2011) Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 50: 136-142.
27. Farid WR, Pan Q, van der Meer AJ, de Ruiter PE, Ramakrishnaiah V, et al. (2012) Hepatocyte-derived micrornas as serum biomarker of hepatic injury and rejection after liver transplantation. Liver Transpl 18: 290-297.
28. Kogure T, Lin WL, Yan IK, Braconi C, Patel T, (2011) Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology. 54: 1237-1248.
29. Jalan R, Hayes PC, (1995) Review article: quantitative tests of liver function. Aliment Pharmacol Ther 9: 263-270.